NSTL国家科技图书文献中心

1. Advances in reversible covalent kinase inhibitors NSTL国家科技图书文献中心

Zheng Zhao | Philip E. Bourne - 《Medicinal research reviews》 - 2025,45(2) - 629～653 - 共25页

摘要：Abstract Reversible covalent kinase inhibitors | (RCKIs) are a class of novel kinase inhibitors | show the selectivity of covalent kinase inhibitors | attracting increasing attention because they simultaneously | yet avoid permanent protein‐modification‐induced

关键词： binding modes | drug discovery | kinase inhibitors | privileged warheads | reversible‐covalent kinase inhibitors

2. Development of asparagine endopeptidase inhibitors for treating neurodegenerative diseases NSTL国家科技图书文献中心

Xin Meng | Bowei Li ... - 《Trends in molecular medicine》 - 2025,31(4) - 359～372 - 共14页

摘要： AEP inhibitors* has emerged as a promising* | disease progression. Various AEP inhibitors* have been* | , antibody-based, and natural inhibitors. Substrate-mimetic | and covalent inhibitors* show significant potential* | noncovalent inhibitors* offer reversible modulation*

关键词： asparagine endopeptidase (AEP); legumain; neurodegenerative diseases; peptide-based inhibitors

3. KRAS inhibitors in drug resistance and potential for combination therapy NSTL国家科技图书文献中心

Rathod, Lala S. | Sakle, Nikhil S.... - 《Tumori Journal.》 - 2025,111(1) - 20～40 - 共21页

摘要： KRAS(G12C) inhibitors* (sotorasib and adagrasib) for* | on covalent KRAS(G12C) inhibitors* have rapidly* | ) inhibitors. | Kirsten Rat Sarcoma (KRAS) is a potent target | for cancer therapy because it acts as a signaling

关键词： KRAS(G12C) inhibitors | resistance | combination therapy | KRAS(G12D) reversible inhibitors | MTRX1133 | adagrasib | sotorasib

4. Emerging Role of Natural Topoisomerase Inhibitors as Anticancer agents NSTL国家科技图书文献中心

Sahu, Sanjeev Kumar | Vyas, Manish ... - 《Medicinal chemistry》 - 2025,21(3) - 195～210 - 共16页

摘要： to develop catalytic inhibitors* of topoisomerases* | inhibitors. As a result, biologists, organic chemists, and | focused on topoisomerase inhibitors, their mechanisms of | action, and different types of topoisomerase inhibitors | topoisomerase inhibitor* molecules and regulatory proteins*

关键词： Anticancer | DNA topoisomerase | topoisomerase inhibitors | topoisomerase I | topoisomerase II inhibitors | natural compound

5. Withdrawal pain following patients discontinuing Trk inhibitors NSTL国家科技图书文献中心

Chin, Alan | Lindsay, Sheila ... - 《Journal of oncology pharmacy practice》 - 2025,31(1) - 147～150 - 共4页

摘要： pain following discontinuation of Trk inhibitors* and* | Trk inhibitor* with the onset of withdrawal pain* | this pain including restarting of Trk inhibitor | , tapering of Trk inhibitor* on discontinuation, minimizing* | inhibitor treatment and highlight the need for patient

关键词： NTRK | Trk inhibitors | larotrectinib | entrectinib | withdrawal pain

6. Management of metastatic melanoma with combinations including PD-1 inhibitors NSTL国家科技图书文献中心

Maul, Lara Valeska | Ramelyte, Egle ... - 《Expert opinion on biological therapy》 - 2025,25(5) - 1～12 - 共12页

摘要： inhibitors (ICIs) has revolutionized the landscape of | with PD-1 inhibitors* through PubMed database research* | IntroductionMelanoma is among the most | immunogenic malignancies. The advent of immune checkpoint | melanoma treatment. Long-term durable cancer control is

关键词： CTLA-4 inhibitor | immune checkpoint inhibitors | LAG-3 inhibitor | melanoma | PD-1 inhibitors | TIGIT

7. Binding-Site Switch for Protein Kinase CK2 Inhibitors NSTL国家科技图书文献中心

Dylan Grenier | Muriel Gelin ... - 《ChemMedChem》 - 2025,20(8) - e202400868～16 - 共16页

摘要： and viral infections.Several types of CK2 inhibitors | have been developed,including inhibitors* that bind to* | the catalytic ATP-site,bivalent inhibitors* that* | inhibitors that target the CK2α/CK2β | interface.Interestingly,the bivalent inhibitor* AB668 shares a similar*

关键词： Protein kinase 2 | inhibitors | protein-protein interface | fragment | Biolayer interferometry

8. PCSK9 Inhibitors - A New Hope for Dyslipidemia in HIV NSTL国家科技图书文献中心

Datla, Sanjana | Kumar, Sundeep - 《Cardiology in review.》 - 2025,33(2) - 112～113 - 共2页

摘要：/kexin type 9 inhibitors* have shown promising results* | Cardiovascular disease has become | increasingly prevalent in the HIV population. Antiretroviral | therapy and HIV itself independently increase the risk | of dyslipidemia. While statins are currently the

关键词： HIV | dyslipidemia | statins | PCSK9 inhibitors | antiretroviral therapy

9. Treatment of Chronic Pouchitis With JAK Inhibitors: Results from A Large Multicenter Database NSTL国家科技图书文献中心

Alsakarneh, Saqr | Desai, Aakash ... - 《Inflammatory bowel diseases》 - 2025,31(2) - 597～600 - 共4页

摘要： Janus kinase inhibitors* in treating chronic pouchitis* | . While showing relative safety, Janus kinase inhibitors | This retrospective study assessed the use of | demonstrated effectiveness in <50% of cases, cautioning | against their use as first-line agents. Larger

关键词： Janus kinase inhibitors | pouchitis | JAK inhibitors | ulcerative colitis | chronic

10. Why think twice before prescribing proton pump inhibitors NSTL国家科技图书文献中心

Lemmens, An-Sofie | Huysentruyt, Koen ... - 《European journal of pediatrics.》 - 2025,184(3) - Article 227～Article 227 - 共6页

摘要：Proton pump inhibitors* (PPIs) represent a* | response.What is known:center dot Proton-pump inhibitors* are* | class of drugs most prominently known for their use in | acid-related disorders. Omeprazole, a drug belonging | to this class, is among the top 10 most prescribed

摘要：Abstract Reversible covalent kinase inhibitors | (RCKIs) are a class of novel kinase inhibitors | show the selectivity of covalent kinase inhibitors | attracting increasing attention because they simultaneously | yet avoid permanent protein‐modification‐induced

关键词： binding modes | drug discovery | kinase inhibitors | privileged warheads | reversible‐covalent kinase inhibitors

摘要： AEP inhibitors* has emerged as a promising* | disease progression. Various AEP inhibitors* have been* | , antibody-based, and natural inhibitors. Substrate-mimetic | and covalent inhibitors* show significant potential* | noncovalent inhibitors* offer reversible modulation*

关键词： asparagine endopeptidase (AEP); legumain; neurodegenerative diseases; peptide-based inhibitors

摘要： KRAS(G12C) inhibitors* (sotorasib and adagrasib) for* | on covalent KRAS(G12C) inhibitors* have rapidly* | ) inhibitors. | Kirsten Rat Sarcoma (KRAS) is a potent target | for cancer therapy because it acts as a signaling

关键词： KRAS(G12C) inhibitors | resistance | combination therapy | KRAS(G12D) reversible inhibitors | MTRX1133 | adagrasib | sotorasib

关键词： Anticancer | DNA topoisomerase | topoisomerase inhibitors | topoisomerase I | topoisomerase II inhibitors | natural compound

摘要： pain following discontinuation of Trk inhibitors* and* | Trk inhibitor* with the onset of withdrawal pain* | this pain including restarting of Trk inhibitor | , tapering of Trk inhibitor* on discontinuation, minimizing* | inhibitor treatment and highlight the need for patient

关键词： NTRK | Trk inhibitors | larotrectinib | entrectinib | withdrawal pain

摘要： inhibitors (ICIs) has revolutionized the landscape of | with PD-1 inhibitors* through PubMed database research* | IntroductionMelanoma is among the most | immunogenic malignancies. The advent of immune checkpoint | melanoma treatment. Long-term durable cancer control is

关键词： CTLA-4 inhibitor | immune checkpoint inhibitors | LAG-3 inhibitor | melanoma | PD-1 inhibitors | TIGIT

摘要： and viral infections.Several types of CK2 inhibitors | have been developed,including inhibitors* that bind to* | the catalytic ATP-site,bivalent inhibitors* that* | inhibitors that target the CK2α/CK2β | interface.Interestingly,the bivalent inhibitor* AB668 shares a similar*

关键词： Protein kinase 2 | inhibitors | protein-protein interface | fragment | Biolayer interferometry

摘要：/kexin type 9 inhibitors* have shown promising results* | Cardiovascular disease has become | increasingly prevalent in the HIV population. Antiretroviral | therapy and HIV itself independently increase the risk | of dyslipidemia. While statins are currently the

关键词： HIV | dyslipidemia | statins | PCSK9 inhibitors | antiretroviral therapy

摘要： Janus kinase inhibitors* in treating chronic pouchitis* | . While showing relative safety, Janus kinase inhibitors | This retrospective study assessed the use of | demonstrated effectiveness in <50% of cases, cautioning | against their use as first-line agents. Larger

关键词： Janus kinase inhibitors | pouchitis | JAK inhibitors | ulcerative colitis | chronic

摘要：Proton pump inhibitors* (PPIs) represent a* | response.What is known:center dot Proton-pump inhibitors* are* | class of drugs most prominently known for their use in | acid-related disorders. Omeprazole, a drug belonging | to this class, is among the top 10 most prescribed

关键词： Proton pump inhibitors | Omeprazole | Gastric mucosa

4008-161-200 800-990-8900

国家科技图书文献中心

摘要：Abstract Reversible covalent kinase inhibitors | (RCKIs) are a class of novel kinase inhibitors | show the selectivity of covalent kinase inhibitors | attracting increasing attention because they simultaneously | yet avoid permanent protein‐modification‐induced

关键词： binding modes | drug discovery | kinase inhibitors | privileged warheads | reversible‐covalent kinase inhibitors

摘要： AEP inhibitors has emerged as a promising | disease progression. Various AEP inhibitors have been | , antibody-based, and natural inhibitors. Substrate-mimetic | and covalent inhibitors show significant potential | noncovalent inhibitors offer reversible modulation

关键词： asparagine endopeptidase (AEP); legumain; neurodegenerative diseases; peptide-based inhibitors

摘要： KRAS(G12C) inhibitors (sotorasib and adagrasib) for | on covalent KRAS(G12C) inhibitors have rapidly | ) inhibitors. | Kirsten Rat Sarcoma (KRAS) is a potent target | for cancer therapy because it acts as a signaling

关键词： KRAS(G12C) inhibitors | resistance | combination therapy | KRAS(G12D) reversible inhibitors | MTRX1133 | adagrasib | sotorasib

摘要： to develop catalytic inhibitors of topoisomerases | inhibitors. As a result, biologists, organic chemists, and | focused on topoisomerase inhibitors, their mechanisms of | action, and different types of topoisomerase inhibitors | topoisomerase inhibitor molecules and regulatory proteins

关键词： Anticancer | DNA topoisomerase | topoisomerase inhibitors | topoisomerase I | topoisomerase II inhibitors | natural compound

摘要： pain following discontinuation of Trk inhibitors and | Trk inhibitor with the onset of withdrawal pain | this pain including restarting of Trk inhibitor | , tapering of Trk inhibitor on discontinuation, minimizing | inhibitor treatment and highlight the need for patient

关键词： NTRK | Trk inhibitors | larotrectinib | entrectinib | withdrawal pain

摘要： inhibitors (ICIs) has revolutionized the landscape of | with PD-1 inhibitors through PubMed database research | IntroductionMelanoma is among the most | immunogenic malignancies. The advent of immune checkpoint | melanoma treatment. Long-term durable cancer control is

关键词： CTLA-4 inhibitor | immune checkpoint inhibitors | LAG-3 inhibitor | melanoma | PD-1 inhibitors | TIGIT

摘要： and viral infections.Several types of CK2 inhibitors | have been developed,including inhibitors that bind to | the catalytic ATP-site,bivalent inhibitors that | inhibitors that target the CK2α/CK2β | interface.Interestingly,the bivalent inhibitor AB668 shares a similar

关键词： Protein kinase 2 | inhibitors | protein-protein interface | fragment | Biolayer interferometry

摘要：/kexin type 9 inhibitors have shown promising results | Cardiovascular disease has become | increasingly prevalent in the HIV population. Antiretroviral | therapy and HIV itself independently increase the risk | of dyslipidemia. While statins are currently the

关键词： HIV | dyslipidemia | statins | PCSK9 inhibitors | antiretroviral therapy

摘要： Janus kinase inhibitors in treating chronic pouchitis | . While showing relative safety, Janus kinase inhibitors | This retrospective study assessed the use of | demonstrated effectiveness in <50% of cases, cautioning | against their use as first-line agents. Larger

关键词： Janus kinase inhibitors | pouchitis | JAK inhibitors | ulcerative colitis | chronic

摘要：Proton pump inhibitors (PPIs) represent a | response.What is known:center dot Proton-pump inhibitors are | class of drugs most prominently known for their use in | acid-related disorders. Omeprazole, a drug belonging | to this class, is among the top 10 most prescribed

关键词： Proton pump inhibitors | Omeprazole | Gastric mucosa

4008-161-200 800-990-8900

国家科技图书文献中心

摘要： AEP inhibitors* has emerged as a promising* | disease progression. Various AEP inhibitors* have been* | , antibody-based, and natural inhibitors. Substrate-mimetic | and covalent inhibitors* show significant potential* | noncovalent inhibitors* offer reversible modulation*

摘要： KRAS(G12C) inhibitors* (sotorasib and adagrasib) for* | on covalent KRAS(G12C) inhibitors* have rapidly* | ) inhibitors. | Kirsten Rat Sarcoma (KRAS) is a potent target | for cancer therapy because it acts as a signaling

摘要： pain following discontinuation of Trk inhibitors* and* | Trk inhibitor* with the onset of withdrawal pain* | this pain including restarting of Trk inhibitor | , tapering of Trk inhibitor* on discontinuation, minimizing* | inhibitor treatment and highlight the need for patient

摘要： inhibitors (ICIs) has revolutionized the landscape of | with PD-1 inhibitors* through PubMed database research* | IntroductionMelanoma is among the most | immunogenic malignancies. The advent of immune checkpoint | melanoma treatment. Long-term durable cancer control is

摘要： and viral infections.Several types of CK2 inhibitors | have been developed,including inhibitors* that bind to* | the catalytic ATP-site,bivalent inhibitors* that* | inhibitors that target the CK2α/CK2β | interface.Interestingly,the bivalent inhibitor* AB668 shares a similar*

摘要：/kexin type 9 inhibitors* have shown promising results* | Cardiovascular disease has become | increasingly prevalent in the HIV population. Antiretroviral | therapy and HIV itself independently increase the risk | of dyslipidemia. While statins are currently the

摘要： Janus kinase inhibitors* in treating chronic pouchitis* | . While showing relative safety, Janus kinase inhibitors | This retrospective study assessed the use of | demonstrated effectiveness in <50% of cases, cautioning | against their use as first-line agents. Larger

摘要：Proton pump inhibitors* (PPIs) represent a* | response.What is known:center dot Proton-pump inhibitors* are* | class of drugs most prominently known for their use in | acid-related disorders. Omeprazole, a drug belonging | to this class, is among the top 10 most prescribed